NANOTEC and GPO to upgrade drug innovation in Thailand

Published: 5-Jul-2011
Media Research & Development

To support projected growth of pharma market in the region

Thailand’s National Nanotechnology Centre (NANOTEC) and the Government Pharmaceutical Organisation (GPO) have signed a strategic research collaboration agreement to focus on drug discovery using nanotechnology.

The partnership will help upgrade the research capabilities of the two Thai agencies and promote national competitiveness, said Soontorn Vorakul, acting managing director for the GPO.

‘The focus of the research collaboration will be in the area of cosmeceutical and drug delivery using nanotechnology,’ he said.

Professor Sirirurg Songsivilai, executive director of NANOTEC, added that the opportunities for nanotechnology in pharmaceutical manufacturing and development are enormous.

‘It is clear that the international pharmaceutical industry has embraced nanotechnology research in their manufacturing. It is essential for the GPO and NANOTEC to join forces and share expertise if we are to keep pace with drug discovery,’ he said.

Thailand will be the eighth largest economy in the Asia Pacific region by 2016, according to the Economist Intelligence Unit (EIU). GDP growth is projected to increase to 7.1% in the same period.

The EIU also projects an annual growth rate of around 0.7% and the population to be the ninth largest in the Asia Pacific region in five years’ time. The elderly population is also rising; Thailand is expected to have the eighth highest proportion in the Asia Pacific region by 2016.

By 2016 it is estimated that Thailand will have the seventh largest pharmaceutical market in the Asia Pacific region.

See more

You may also like

Research & Development

Merck and Moderna announce 5-year data for intismeran autogene in combination with KEYTRUDA

Read more
Eight Phase II and Phase III clinical trials are under way across multiple tumour types, including melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma

Trending Articles

  1. FDA and EMA issue guiding principles for AI in drug development The set of ten principles gives broad guidance on AI use in evidence generation and monitoring across all phases of a medicine, from early research and clinical trials to manufacturing and safety monitoring
  2. Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
  3. Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
  4. One in ten Britons are using or interested in using GLP-1s for weight loss, according to new research GLP-1 use and interest was more prevalent among women, as well as those who reported difficulties with their finances or who had experienced psychological distress within the previous month
  5. Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our clients through a globally integrated network of facilities in North America, Europe and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs and finished dosage forms. We also offer specialized services such as development and manufacture of highly potent APIs, antibody drug conjugation, sterile fill/finish with and without containment, and potent solid oral drug product. Our capability as an integrated service provider & experience with various technologies enables us to serve innovator and generic companies worldwide.

Upcoming event

Pharmapack

21–22 January 2026 | Exhibition | Paris, France See all

You may also like

Research & Development

Merck and Moderna announce 5-year data for intismeran autogene in combination with KEYTRUDA

Eight Phase II and Phase III clinical trials are under way across multiple tumour types, including melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma
Manufacturing

Cellistic launches new iPSC-based GMP platforms to boost cell therapy development

Echo-T, Echo-Cardio, and Echo-Endothelial enable scalable immuno-oncology and regenerative therapies
Research & Development

FDA and EMA issue guiding principles for AI in drug development

The set of ten principles gives broad guidance on AI use in evidence generation and monitoring across all phases of a medicine, from early research and clinical trials to manufacturing and safety monitoring
Drug Delivery

Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody

The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development

FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design

The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline
Research & Development

Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive

Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
Research & Development

Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic

Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
Subscribe now